Skip to main content
. 2023 Aug 31;16:17562848231196357. doi: 10.1177/17562848231196357

Table 1.

Characteristics of the studies included in the systematic review and meta-analysis.

First authors Year Country Study design Treatment line Tailored determinant Patients (tailored/empiric) Eradication regime Eradication rate of TT Eradication rate of ET
Tailored regimens Empiric regimens ITT PP ITT PP
Cha 2021 Korea RCT 1 DPO-PCR 182/178 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days
CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days
BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + RAB 20 mg BID, 7 days 66.3% (118/178) 81.4% (118/145) 78.0% (142/182) 88.8% (142/160)
Choi 2021 Korea RCT 1 DPO-PCR 110/107 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days
CLA-r: BIS 300 mg QID + MET 500 mg BID + TET 500 mg QID + LAN 30 mg BID, 10 days
AMO 1000 mg BID + MET 500 mg BID + CLA 500 mg BID + LAN 30 mg BID, 10 days 82.7% (91/110) 90.1% (91/101) 82.2% (88/107) 91.6% (87/95)
Cho 2021 Korea RCT 1 DPO-PCR 141/141 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + PAN 40 mg BID, 7 days
CLA-r: BIS 300 mg QID + MET 500 mg TID + TET 500 mg QID + PAN 40 mg BID, 7 days
BIS 600 mg BID + AMO 1000 mg BID + MET 750 mg BID + PAN 40 mg BID, 14 days 80.9% (114/141) 89.0% (113/127) 85.8% (121/141) 93.5% (116/124)
Delchier 2020 France RCT 1 and 2 GenoType HelicoDR® PCR 266/260 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + PPI BID, 7 days
CLA-r + LEV-s: AMO 1000 mg BID + LEV 250 mg BID + PPI BID, 10 days
CLA-r + LEV-r: AMO 1000 mg BID + MET 500 mg BID + PPI BID, 14 days
(OME 20 mg BID or ESO 20 mg BID or LAN 30 mg BID or PAN 40 mg BID or RAB 20 mg BID)
First line: AMO 1000 mg BID + CLA 500 mg BID + PPI BID, 7 days
Second line: AMO 1000 mg BID + MET 500 mg BID + PPI BID, 14 days (OME 20 mg BID or ESO 20 mg BID or LAN 30 mg BID or PAN 40 mg BID or RAB 20 mg BID)
85.5% (177/207) 86.5% (173/200) 73.1% (152/208) 74.4% (151/203)
Furuta 2007 Japan RCT 1 PCR 150/150 CLA-s: AMO 500 mg TID + CLA 200 mg TID + LAN 15 mg/30 mg BID (According to CYP2C19), 7 days
CLA-r: AMO 500 mg QID + LAN 15 mg/30 mg BID (According to CYP2C19), 14 days
AMO 750 mg BID + CLA 400 mg BID + LAN 30 mg BID, 7 days 96.0% (144/150) 96.6% (144/149) 70.0% (105/150) 72.9% (105/144)
Hsieh 2022 China RCT 1 PCR-RLFP 91/91 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days
CLA-r, LEV-s: AMO 1000 mg BID + LEV 500 mg QD + RAB 20 mg BID, 7 days
CLA-r, LEV-r: AMO 1000 mg BID (14 days) + CLA 500 mg BID (7 days) + MET 500 mg BID (7 days) or AMO 1000 mg QID + RAB 20 mg QID, 14 days
AMO 750 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days 89.0% (81/99) 91.0% (81/89) 75.8% (69/91) 79.3% (69/87)
Kawai 2008 Japan RCT 1 PCR 35/35 CLA-s: AMO 750 mg BID + CAM 400 mg BID + LAP 30 mg BID, 7 days
CLA-r/mixed infections: AMO 750 mg BID + MET 250 mg BID + RAB 10 mg BID, 7 days
AMO 750 mg BID + CAM 400 mg BID + LAN 30 mg BID, 7 days 94.3% (33/35) 94.3% (33/35) 71.4% (25/35) 78.1% (25/32)
Kim 2020 Korea RCT 1 DPO-PCR 36/36 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + ESO 40 mg BID, 10 days
CLA-r: BIS 300 mg BID + TET 500 mg QID + MET 500 mg TID + ESO 40 mg BID, 10 days
AMO 1000 mg BID + CLA 500 mg BID + ESO 40 mg BID, 10 days 88.9% (32/36) 97.0% (32/33) 75.0% (27/36) 81.8% (27/33)
Kim 2022 Korea RCT 1 DPO-PCR 145/145 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 14 days
CLA-r: TET 1000 mg QID + MET 500 mg TID + BIS 120 mg QID + RAB 20 mg BID, 14 days
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg + RAB 20 mg BID, 14 days 85.5% (124/145) 94.6% (122/129) 82.8% (120/145) 88.6% (117/132)
Lee 2013 Korea RCT 1 DPO-PCR 218/616 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days
CLA-r: AMO 1000 mg BID + MET 500 mg TID + RAB 20 mg BID, 7 days
APC: AMO 1000 mg BID + CLA 500 mg BID + RAB 20 mg BID, 7 days
APM: AMO 1000 mg BID + MET TID + RAB 20 mg BID, 7 days
80.7% (176/218) 91.2% (176/193) 70.3% (433/616) 77.5% (433/559)
Liou 2018 China RCT 3 and more PCR 205/205 (EPZ 40 mg BID + AMP 1000 mg BID), 7 days + (EPZ 40 mg BID + MET 500 mg BID + LEV 250 mg/CLA 500 mg/TET 500 mg BID) (According to genotypic resistance), 7 days (EPZ 40 mg BID + AMP 1000 mg BID), 7 days + (EPZ 40 mg BID + MET 500 mg BID + LEV 250 mg/CLA 500 mg/TET 500 mg BID), 7 days 78.0% (160/205) 78.4% (156/199) 72.2% (148/205) 74.4% (145/195)
Ong 2019 Korea RCT 1 PCR 201/196 CLA-s: AMO 1000 mg BID + CLA 500 mg BID + LAN 30 mg BID, 14 days
CLA-r: AMO 1000 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days
AMO 1000 mg BID + CLA 500 mg BID + MET 500 mg BID + LAN 30 mg BID, 14 days 81.6% (164/201) 86.5% (154/178) 86.2% (169/196) 90.2% (157/174)

AMO, amoxicillin; APM, amoxicillin + rabeprazole + metronidazole; APM, amoxicillin + rabeprazole + clarithromycin; BID, two times a day; BIS, bismuth; CLA, clarithromycin; CLA-r, clarithromycin resistant; CLA-s, clarithromycin sensitive; DPO-PCR, dual priming oligonucleotide polymerase chain reaction; EPZ, esomeprazole; ET, empirical therapy; FUR, furazolidone; LAN, lansoprazole; LEV, levofloxacin; LEV-r, levofloxacin resistant; LEV-s, levofloxacin sensitive; MET, metronidazole; MET-r, metronidazole resistant; MET-s, metronidazole sensitive; PCR-RLFP, polymerase chain reaction-restriction fragment length polymorphism; PPI, proton-pump inhibitor; QD, once a day; QID, four times a day; RAB, rabeprazole; RCT, randomized control trial; TET, tetracycline; TID, three times a day; TT, tailored therapy.